FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024750102> ?p ?o ?g. }

• W2024750102 endingPage "492" @default.
• W2024750102 startingPage "483" @default.
• W2024750102 abstract "Background Prescription omega-3-acid ethyl esters (POM3) reduce triglycerides (TG) and very low-density lipoprotein cholesterol and increase high-density lipoprotein cholesterol (HDL-C) in patients with hypertriglyceridemia. Objective To examine the effects of POM3 plus atorvastatin versus placebo plus atorvastatin on lipoprotein particle concentrations and sizes, apolipoprotein (Apo) CIII, and lipoprotein-associated phospholipase A2 mass in subjects with mixed dyslipidemia. Methods After a 4-week diet lead in, men and women with non-HDL-C >160 mg/dL and TG 250-599 mg/dL, while taking no lipid-altering drugs, received double-blind 4 g/d POM3 (n = 118) or placebo (n = 119) with open-label atorvastatin 10 mg/d for 8 weeks, followed by escalation to 20 mg/d atorvastatin for 4 weeks, then 40 mg/d atorvastatin for 4 weeks. Results Total low-density lipoprotein particle (LDL-P) concentration decreased significantly from baseline, and the reductions did not differ between the POM3 and placebo groups (−659.7 vs −624.4 nmol/L, P = .181). With POM3, compared with placebo, small LDL-P concentration decreased (P = .026), large LDL-P concentration increased (P < .001), mean LDL-P size increased (P = .001), a larger fraction of subjects switched from LDL subclass pattern B to A, and Apo CIII and lipoprotein-associated phospholipase A2 levels were reduced (P < .001). The incremental effects of POM3 were similar across atorvastatin doses for most variables. Conclusion This analysis supports the view that LDL-P concentration is not increased by POM3 plus atorvastatin, relative to atorvastatin monotherapy, and is associated with potentially favorable shifts in LDL-P subfractions, Apo CIII and lipoprotein-associated phospholipase A2 in mixed dyslipidemia. Prescription omega-3-acid ethyl esters (POM3) reduce triglycerides (TG) and very low-density lipoprotein cholesterol and increase high-density lipoprotein cholesterol (HDL-C) in patients with hypertriglyceridemia. To examine the effects of POM3 plus atorvastatin versus placebo plus atorvastatin on lipoprotein particle concentrations and sizes, apolipoprotein (Apo) CIII, and lipoprotein-associated phospholipase A2 mass in subjects with mixed dyslipidemia. After a 4-week diet lead in, men and women with non-HDL-C >160 mg/dL and TG 250-599 mg/dL, while taking no lipid-altering drugs, received double-blind 4 g/d POM3 (n = 118) or placebo (n = 119) with open-label atorvastatin 10 mg/d for 8 weeks, followed by escalation to 20 mg/d atorvastatin for 4 weeks, then 40 mg/d atorvastatin for 4 weeks. Total low-density lipoprotein particle (LDL-P) concentration decreased significantly from baseline, and the reductions did not differ between the POM3 and placebo groups (−659.7 vs −624.4 nmol/L, P = .181). With POM3, compared with placebo, small LDL-P concentration decreased (P = .026), large LDL-P concentration increased (P < .001), mean LDL-P size increased (P = .001), a larger fraction of subjects switched from LDL subclass pattern B to A, and Apo CIII and lipoprotein-associated phospholipase A2 levels were reduced (P < .001). The incremental effects of POM3 were similar across atorvastatin doses for most variables. This analysis supports the view that LDL-P concentration is not increased by POM3 plus atorvastatin, relative to atorvastatin monotherapy, and is associated with potentially favorable shifts in LDL-P subfractions, Apo CIII and lipoprotein-associated phospholipase A2 in mixed dyslipidemia." @default.
• W2024750102 created "2016-06-24" @default.
• W2024750102 creator A5032023438 @default.
• W2024750102 creator A5036954718 @default.
• W2024750102 creator A5045223771 @default.
• W2024750102 creator A5053191013 @default.
• W2024750102 creator A5053831963 @default.
• W2024750102 date "2011-11-01" @default.
• W2024750102 modified "2023-10-14" @default.
• W2024750102 title "Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia" @default.
• W2024750102 cites W1963891642 @default.
• W2024750102 cites W1967425491 @default.
• W2024750102 cites W1970736991 @default.
• W2024750102 cites W1972613225 @default.
• W2024750102 cites W1974805788 @default.
• W2024750102 cites W1976428272 @default.
• W2024750102 cites W1976463891 @default.
• W2024750102 cites W1977600693 @default.
• W2024750102 cites W1982036768 @default.
• W2024750102 cites W1988104806 @default.
• W2024750102 cites W1988610039 @default.
• W2024750102 cites W1990166147 @default.
• W2024750102 cites W1997203658 @default.
• W2024750102 cites W1998826672 @default.
• W2024750102 cites W2006583639 @default.
• W2024750102 cites W2012344261 @default.
• W2024750102 cites W2015846619 @default.
• W2024750102 cites W2023555072 @default.
• W2024750102 cites W2026387613 @default.
• W2024750102 cites W2028872016 @default.
• W2024750102 cites W2036630204 @default.
• W2024750102 cites W2041752824 @default.
• W2024750102 cites W2041882790 @default.
• W2024750102 cites W2057271976 @default.
• W2024750102 cites W2061315559 @default.
• W2024750102 cites W2064715676 @default.
• W2024750102 cites W2066343714 @default.
• W2024750102 cites W2066530607 @default.
• W2024750102 cites W2067335608 @default.
• W2024750102 cites W2078011435 @default.
• W2024750102 cites W2087383229 @default.
• W2024750102 cites W2089110021 @default.
• W2024750102 cites W2089286420 @default.
• W2024750102 cites W2092831846 @default.
• W2024750102 cites W2106620061 @default.
• W2024750102 cites W2107928904 @default.
• W2024750102 cites W2108709323 @default.
• W2024750102 cites W2109806543 @default.
• W2024750102 cites W2120623105 @default.
• W2024750102 cites W2121209370 @default.
• W2024750102 cites W2124872768 @default.
• W2024750102 cites W2125628785 @default.
• W2024750102 cites W2132010550 @default.
• W2024750102 cites W2132263678 @default.
• W2024750102 cites W2135212903 @default.
• W2024750102 cites W2142284567 @default.
• W2024750102 cites W2143340286 @default.
• W2024750102 cites W2149409142 @default.
• W2024750102 cites W2152354184 @default.
• W2024750102 cites W2153686276 @default.
• W2024750102 cites W2153722087 @default.
• W2024750102 cites W2154080377 @default.
• W2024750102 cites W2159615638 @default.
• W2024750102 cites W2160942744 @default.
• W2024750102 cites W2172164503 @default.
• W2024750102 cites W2614708982 @default.
• W2024750102 cites W4230870013 @default.
• W2024750102 cites W4235659103 @default.
• W2024750102 doi "https://doi.org/10.1016/j.jacl.2011.09.001" @default.
• W2024750102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22108152" @default.
• W2024750102 hasPublicationYear "2011" @default.
• W2024750102 type Work @default.
• W2024750102 sameAs 2024750102 @default.
• W2024750102 citedByCount "72" @default.
• W2024750102 countsByYear W20247501022012 @default.
• W2024750102 countsByYear W20247501022013 @default.
• W2024750102 countsByYear W20247501022014 @default.
• W2024750102 countsByYear W20247501022015 @default.
• W2024750102 countsByYear W20247501022016 @default.
• W2024750102 countsByYear W20247501022017 @default.
• W2024750102 countsByYear W20247501022018 @default.
• W2024750102 countsByYear W20247501022019 @default.
• W2024750102 countsByYear W20247501022020 @default.
• W2024750102 countsByYear W20247501022021 @default.
• W2024750102 countsByYear W20247501022022 @default.
• W2024750102 crossrefType "journal-article" @default.
• W2024750102 hasAuthorship W2024750102A5032023438 @default.
• W2024750102 hasAuthorship W2024750102A5036954718 @default.
• W2024750102 hasAuthorship W2024750102A5045223771 @default.
• W2024750102 hasAuthorship W2024750102A5053191013 @default.
• W2024750102 hasAuthorship W2024750102A5053831963 @default.
• W2024750102 hasConcept C126322002 @default.
• W2024750102 hasConcept C134018914 @default.
• W2024750102 hasConcept C142724271 @default.
• W2024750102 hasConcept C204787440 @default.
• W2024750102 hasConcept C27081682 @default.
• W2024750102 hasConcept C2776104379 @default.
• W2024750102 hasConcept C2776919658 @default.

• next